

BIOCON - 'Cost' of Pfizer Deal Showing Up

<https://marketpublishers.com/r/B95C8D3E984EN.html>

Date: January 2012

Pages: 10

Price: US\$ 140.00 (Single User License)

ID: B95C8D3E984EN

Abstracts

We reiterate our Market Perform rating on BIOS with a reduced target price following a cut in our estimates after is below than expected Q3FY12 result. Licensing income revenue decline of 62% and profit decline of 89% remained the biggest reason for a 17% and 14% Y-o-Y reduction in Q3 FY12 EBITDA and net profit. We have always maintained that the Pfizer-Biocon deal is at best a cash neutral deal for Biocon. This is due to the development expenses (including clinical trials) and capex related to the insulin manufacturing.

We cut our FY13 and 14 estimates by 20% largely owing to licensing income. At the same time, we now do not give any value to the Pfizer deal besides the profit earned from licensing income. We thus revise our target price by applying a PE of 17x on our FY13 earnings. We reiterate our Market Perform with reduced target price of Rs.283.

Contents

COMPANIES MENTIONED

BIOCON

I would like to order

Product name: BIOCON - 'Cost' of Pfizer Deal Showing Up

Product link: <https://marketpublishers.com/r/B95C8D3E984EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B95C8D3E984EN.html>